|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the setting of the immunogenic B16-Ova (Ovalbumin) expressing melanoma model, local injection of the CpG oligonucleotide TLR9 agonist ODN1826 combined with systemic CTLA-4 blockade cured 45% of mice of both their treated and an untreated tumor on the opposite flank demonstrating the synergistic potential of this combination.
|
31771649 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand CpG A can kill breast cancer cells <i>in vitro</i> and inhibit tumor growth in vivo.
|
31093508 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moreover, the presence of TLR9-1237 TC/CC + TLR9-1486 CC genotypes potentiate the risk for this neoplasm (OR = 18.57; 95%CI: 5.06-68.15, <i>P</i> < 0.0001).
|
31798780 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that tumor-released DNA causes accumulation, antigen uptake, and maturation of dendritic cells (DCs) in the tumor in a TLR9-dependent manner.
|
31619293 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further show that the local delivery of TLR9 agonists converts the tolerogenic tumor microenvironment into an immunopermissive one, which may benefit current immunotherapeutic anticancer strategies by enhancing innate and adaptive tumor-associated immune cell responses.
|
30546946 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
|
31090157 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In gastro-esophageal junction adenocarcinoma subgroup, only the mRNA expression of TLR-7 and protein concentrations of TLR-4, TLR-7 and TLR-9 were significantly higher in tumors than in normal mucosa (p < 0.05).
|
29968427 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results reinforce the concept that i.t. delivery of TLR9 agonists alters the tumor microenvironment by improving the antitumor activity of both innate and adaptive immune cells.<b>Significance:</b> Intratumoral delivery of CpG-B disrupts the tolerogenic tumor microenvironment and inhibits tumor growth.<i></i>.
|
29588348 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR9-short hairpin RNA was used to knockdown TLR-9 and determine its role in tumor cell response to DNA.
|
29605400 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the concurrence of TLR9 activation with STAT3 inhibition in the same cellular compartment is indispensable for overcoming tumor immune tolerance and effective antitumor immunity against prostate cancer.
|
30337279 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The result showed that the high expression of TLR9 was correlated with tumor poorly differentiation, invasion and liver metastasis, the abnomal increasing levels of CEA in blood.
|
30271180 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study characterizes a strategy to apply localized TLR9 stimulation to a tumor type not accessible for direct injection, a strategy that may expand the therapeutic potential of PD-1 blockade in non-small cell lung cancer.<b>Significance:</b> These findings demonstrate that local delivery of a toll-like receptor 9 agonist can change the immune content of an entire organ and enhance the efficacy of immune checkpoint inhibition.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/17/4943/F1.large.jpg <i></i>.
|
29945961 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied the prognostic significance of tumor Toll like receptor-9 (TLR9) protein expression among African American (AA) triple negative breast cancer (TNBC) patients.
|
28886076 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study explored the correlation of TLR9 expression with tumor location and survival outcomes in patients with supratentorial GBM.
|
27744078 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent evidence reveals over-expression and functionality of TLR9 in a wide variety of cancer cells and its contribution to tumor cell proliferation and survival.
|
28106541 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction.
|
28370295 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of a suboptimal dose of MVATG9931 and the type B TLR9 ligand Litenimod (Li28) markedly increased survival in a subcutaneous RMA-MUC1 tumor model compared to the treatment with MVATG9931 or Li28 alone.
|
28012777 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Data revealed that some TLRs participate in oral carcinogenesis since TLR5 and TLR9 promote tumor growh, whereas TLR3 is closely involved to anti-cancer properties.
|
28982847 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicate that TLR9 and NFKBIA protein expressions act as independent predictor of survival for the diagnosis of glioma and a prognostic biomarker for those with a tumor at an advanced pathological grade.
|
27538656 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The TLR 9 expression was lower in HPV-positive tumors compared with HPV-negative tumors.
|
25941114 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, TLR9 is overexpressed in both hypoxic tumor cells in vitro and in human hepatocellular cancer (HCC) specimens; and, injection in mice to knockdown either HMGB1 or TLR9 from HCC cells suppressed tumor growth in vivo.
|
25681553 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These mice had significantly worse survival and a higher tumor burden than K-ras(LA1) TLR9(-/-) mice.
|
23913633 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Esophageal carcinomas exhibited TLR9 expression that was positively associated with tumor size, location and TNM stage (P<0.05).
|
24647486 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The absence of detectable TLR9 mRNA expression was associated with an absence of significance in the correlation between IL6 and NFκB or IRF5, but not that between IRF7 and IFNAR1 in both the tumor and the normal tissues.
|
25546690 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
|
25168392 |
2014 |